B
Bartulis Sarah
Researcher at Novartis
Publications - 7
Citations - 622
Bartulis Sarah is an academic researcher from Novartis. The author has contributed to research in topics: Kinase & Serine. The author has an hindex of 5, co-authored 7 publications receiving 592 citations.
Papers
More filters
Journal ArticleDOI
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew Burger,Sabina Pecchi,Allan S. Wagman,Zhi-Jie Ni,Mark Knapp,Thomas Hendrickson,Gordana Atallah,Keith B. Pfister,Zhang Yanchen,Bartulis Sarah,Frazier Kelly,Simon Ng,Aaron Smith,Joelle Verhagen,Joshua Haznedar,Kay Huh,Ed Iwanowicz,Xiaohua Xin,Daniel Menezes,Hanne Merritt,Isabelle Lee,Marion Wiesmann,Susan Kaufman,Kenneth Crawford,Michael Chin,Dirksen E. Bussiere,Kevin Shoemaker,Isabel Zaror,Sauveur-Michel Maira,Charles Voliva +29 more
TL;DR: The structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.
Patent
Pyrimidine derivatives used as pi-3 kinase inhibitors
Burger Matthew,Ni Zhi-Jie,Sabina Pecchi,Gordana Atallah,Bartulis Sarah,Frazier Kelly,Smith Aaron,Joelle Verhagen,Zhang Yanchen,Wagman Allan,Simon Ng,Keith B. Pfister,Daniel Poon,Louie Alicia,Pick Teresa E,Barsanti Paul A,Iwanowicz Edwin,Wendy J. Fantl,Hendrickson Thomas,Mark Knapp,Meritt Hanne,Voliva Charles,Marion Wiesmann,Xin Xiahua +23 more
TL;DR: In this paper, the authors describe the use of 3-kinase inhibitors in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
Patent
Pi-3 kinase inhibitors and methods of their use
Zhi-Jie Ni,Sabina Pecchi,Matthew Burger,Wooseok Han,Aaron Smith,Gordana Atallah,Bartulis Sarah,Frazier Kelly,Joelle Verhagen,Zhang Yanchen,Iwanowicz Edwin,Hendrickson Tom,Mark Knapp,Hanne Merritt,Charles Voliva,Marion Wiesmann,Darren Mark Legrand,Ian J. Bruce,James Dale,Jiong Lan,Levine Barry Haskell,Abran Costales,Liu Jie,Pick Teresa E,Daniel Menezes +24 more
TL;DR: The use of PI 3 kinase inhibitors in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases and G-protein coupled receptors is discussed in this article.
Journal ArticleDOI
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors
Matthew Burger,Mark Knapp,Allan S. Wagman,Zhi-Jie Ni,Thomas Hendrickson,Gordana Atallah,Zhang Yanchen,Frazier Kelly,Joelle Verhagen,Keith B. Pfister,Simon Ng,Aaron Smith,Bartulis Sarah,Hanne Merrit,Marion Weismann,Xiaohua Xin,Joshua Haznedar,Charles Voliva,Ed Iwanowicz,Sabina Pecchi +19 more
TL;DR: The structure-guided optimization of these pyrimidines is described with a focus on replacing the phenol moiety, while maintaining potent target inhibition and improving in vivo properties.
Patent
Pi3 kinase inhibitors and methods of their use
Ni Zhi-Jie,Sabina Pecchi,Burger Matthew,Wooseok Han,Aaron Smith,Gordana Atallah,Bartulis Sarah,Frazier Kelly,Joelle Verhagen,Zhang Yanchen,Iwanowicz Ed,Hendrickson Tom,Mark Knapp,Hanne Merritt,Charles Voliva,Marion Wiesmann,Darren Mark Legrand,Ian Bruce,James Dale,Lan Jiong,Levine Barry Haskell,Abran Costales,Jui Liu,Pick Teresa E,Daniel Menezes +24 more
TL;DR: The use of PI 3 kinase inhibitors in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases and G-protein coupled receptors is discussed in this paper.